The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review

References

• Bray F, Dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol, Biomarkers Prevention 2005;14:1132–42
   PubMed Web of Science ®Google Scholar
• Ferlay JSH, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. IARC CancerBase No 10, 2010 [cited; Available from: http://globocan.iarc.fr/]
   Google Scholar
• Elwood JM, Cole P, Rothman KJ, Kaplan SD. Epidemiology of endometrial cancer. J Natl Cancer Instit 1977;59:1055–60
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Franceschi S, Decarli A, Gallus G, Tognoni G. Risk factors for endometrial cancer at different ages. J Natl Cancer Instit 1984;73:667–71
   PubMed Web of Science ®Google Scholar
• Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005;6:552–3
   PubMed Web of Science ®Google Scholar
• Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of Liver and Endometrial Cancer Risk following Tamoxifen. Lancet 2000;356:881–7
   PubMed Web of Science ®Google Scholar
• Humphrey MM, Apte SM. The use of minimally invasive surgery for endometrial cancer. Cancer Control 2009;16:30–7
   PubMedGoogle Scholar
• Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009;114:121–7
   PubMed Web of Science ®Google Scholar
• Siiteri PK. Steroid hormones and endometrial cancer. Cancer Res 1978;38:4360–6
   PubMed Web of Science ®Google Scholar
• Key TJ, Pike MC. The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205–12
   PubMed Web of Science ®Google Scholar
• Good RG, Moyer DL. Estrogen-progesterone relationships in the development of secretory endometrium. Fertil Steril 1968;19: 37–49
   PubMed Web of Science ®Google Scholar
• Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000;13:295–308
   PubMed Web of Science ®Google Scholar
• Lacey JV Jr, Ioffe OB, Ronnett BM, . Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. Br J Cancer 2008;98: 45–53
   PubMed Web of Science ®Google Scholar
• Lacey JV Jr, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 2009;63:39–44
   PubMed Web of Science ®Google Scholar
• Gruber SB, Thompson WD. A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol Biomarkers Prev 1996;5:411–17
   PubMed Web of Science ®Google Scholar
• Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64:430–3
   PubMed Web of Science ®Google Scholar
• Vasen HF, Wijnen JT, Menko FH, . Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020–7
   PubMed Web of Science ®Google Scholar
• Manchanda R, Menon U, Michaelson-Cohen R, Beller U, Jacobs I. Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynecological perspective. Curr Opin Obstet Gynecol 2009;21:31–8
   PubMed Web of Science ®Google Scholar
• Neven P, Vergote I. Should tamoxifen users be screened for endometrial lesions? Lancet 1998;351:155–7
   PubMed Web of Science ®Google Scholar
• Gadducci A, Spirito N, Baroni E, Tana R, Genazzani AR. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecol Endocrinol 2009;25:683–91
   PubMed Web of Science ®Google Scholar
• Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane database of systematic reviews (Online) 2000(2):CD000402
   Google Scholar
• Peto odds ratio method. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2 [updated September 2009]. Chapter 9.4.4.2. [cited; Available from: www.cochrane-handbook.org/]
   Google Scholar
• Volpe A, Botticelli A, Abrate M, . An intrauterine progesterone contraceptive system (52 mg) used in pre- and peri-menopausal patients with endometrial hyperplasia. Maturitas 1982; 4:73–9
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Malinen H, Sundstrom H, Penttinen J, Kauppila A. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstet Gynecol Scand 1998;77:758–63
   PubMed Web of Science ®Google Scholar
• Intrauterine levonorgestrel and observation or observation alone in preventing atypical endometrial hyperplasia and endometrial cancer in women with hereditary non-polyposis colorectal cancer or Lynch Syndrome. National Institute of Health: Clinical Trials.gov [cited 17th July 2009]; Available from: http://clinicaltrials.gov/ct2/show/record/NCT00566644
   Google Scholar
• A randomized, controlled, comparative study of a levonorgestrel intrauterine system for the prevention of endometrial cancer in patients aged 40–50 with BMI greater than 35. National Instititue of Health: Clinical Trials.gov. [cited 17th July 2009]; Available from: http://clinicaltrials.gov/ct2/show/record/NCT00161226
   Google Scholar
• Suhonen SP, Holmstrom T, Allonen HO, Lahteenmaki P. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril 1995;63:336–42
   PubMed Web of Science ®Google Scholar
• Antoniou G, Kalogirou D, Karakitsos P, Antoniou D, Kalogirou O, Giannikos L. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses. Maturitas 1997; 26:103–11
   PubMed Web of Science ®Google Scholar
• Raudaskoski TH, Lahti EI, Kauppila AJ, Apaja-Sarkkinen MA, Laatikainen TJ. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995;172:114–19
   PubMed Web of Science ®Google Scholar
• Raudaskoski T, Tapanainen J, Tomas E, . Intrauterine 10 μg and 20 μg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002;109:136–44
   PubMed Web of Science ®Google Scholar
• Boon J, Scholten PC, Oldenhave A, Heintz AP. Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT. Maturitas 2003;46:69–77
   PubMed Web of Science ®Google Scholar
• Andersson K, Mattsson LA, Rybo G, Stadberg E. Intrauterine release of levonorgestrel – a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992;79:963–7
   PubMed Web of Science ®Google Scholar
• Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001;8:245–51
   PubMed Web of Science ®Google Scholar
• Riphagen FE. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric 2000;3:199–211
   PubMedGoogle Scholar
• Gardner FJ, Konje JC, Bell SC, . Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. Gynecol Oncol 2009;114:452–6
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Sundstrom H, Penttinen J, Laara E, Pramila S, Kauppila A. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas 1997;26:211–17
   PubMed Web of Science ®Google Scholar
• Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2003;91:526–33
   PubMed Web of Science ®Google Scholar
• Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111:68–73
   PubMed Web of Science ®Google Scholar
• Gardner FJ, Konje JC, Abrams KR, . Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000;356:1711–17
   PubMed Web of Science ®Google Scholar
• Chan SS, Tam WH, Yeo W, . A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 2007;114:1510–15
   PubMed Web of Science ®Google Scholar
• Kesim MD, Aydin Y, Atis A, Mandiraci G. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric 2008;11:252–7
   PubMed Web of Science ®Google Scholar
• Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) – a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006;125:9–28
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Rantala ML, Colau JC, Zahradnik HP, Riphagen FE. The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women. Climacteric 2004;7:404–11
   PubMed Web of Science ®Google Scholar
• Wollter-Svensson LO, Stadberg E, Andersson K, Mattsson LA, Odlind V, Persson I. Intrauterine administration of levonorgestrel 5 and 10 μg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. Acta Obstet Gynecol Scand 1997;76:449–54
   PubMed Web of Science ®Google Scholar
• Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer 2010;126:483–9
   PubMed Web of Science ®Google Scholar
• Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews (Online) 2009(4):CD007245
   Web of Science ®Google Scholar
• Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception 1995;52:269–76
   PubMed Web of Science ®Google Scholar
• Backman T. Benefit-risk assessment of the levonorgestrel intrauterine system in contraception. Drug Saf 2004;27:1185–204
   PubMed Web of Science ®Google Scholar